局部晚期宫颈癌同步放化疗联合图像引导自适应近距离放疗后局部复发患者的结局分析
复发后中位生存47个月,仅3例(10.7%)可接受挽救手术,其中2例无显著并发症存活;局部进展导致75%患者出现严重症状,近距离放疗与复发间隔<1年是2年总生存的预后因素(p=.005)。
要点
- IGABT后局部复发率10.8%,仅5%为孤立局部复发。
- 仅10.7%局部复发患者可手术,转移和盆壁侵犯是主要禁忌。
- 近距离放疗与复发间隔<1年与2年总生存相关(p=.005)。
核心结论
- 挽救手术仅适用于极少数高度选择的IGABT后局部复发患者。
- 局部失败是严重局部症状的主要原因,应通过剂量递增努力实现长期局部控制。
主要发现
- 中位随访4.1年,10.8%(n=28)出现局部复发。
- 局部复发患者中53.6%合并同步淋巴结或远处转移复发,仅13例(占全部患者5%)为孤立局部复发。
- 局部复发后中位生存47个月,末次随访时3例存活。
- 仅3例(10.7%)接受挽救手术,其中2例末次随访时存活且无显著并发症。
- 转移发生和盆壁侵犯是挽救手术的主要禁忌(67.9%)。
关键数值与推荐
- 局部复发后中位生存47个月。
- 仅10.7%局部复发患者可接受挽救手术。
- 转移和盆壁侵犯占挽救手术禁忌的67.9%。
- 近距离放疗与复发间隔<1年与2年总生存相关(p=.005)。
临床怎么用
- 对IGABT后局部复发患者,应评估转移和盆壁侵犯以判断挽救手术可行性。
- 局部失败易导致严重症状,应通过剂量递增优化初始局部控制。
- 近距离放疗后1年内复发者预后较差,需密切随访。
局限性
- 局部复发例数少(n=28),挽救手术例数极少(n=3)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Since dose escalation allowed by image-guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer (LACC), local relapses have become a rare event. Only scarce data are available on the outcome of patients experiencing a local relapse after IGABT. METHODS: Between 2004 and 2016, all consecutive patients treated at Gustave Roussy Institute for LACC and receiving concomitant chemoradiation and IGABT were analysed. Clinical and treatment-related prognostic factors for survival after local relapse were searched, in order to potentially identify patients requiring salvage treatment. RESULTS: Two hundred and fifty-nine patients were treated during this period. With a median follow-up of 4.1 years, 10.8% (n = 28) had a local relapse. Among these patients, 53.6% had synchronous lymph nodes or distant metastatic relapse and only 13 patients (5% of all patients) had isolated local relapse. After local relapse, median survival was 47 months and three patients were alive at last follow-up. Only three patients with local relapse could receive salvage surgery (10.7%). Metastases occurrence and pelvic wall involvement were the main contraindications (67.9%) for salvage surgery. Among the three patients treated with surgery, two are still alive at last follow-up without significant complication. Improved survival was observed among the two patients who could have surgery (p = .02). Local progression led to serious symptoms in 75% of patients. Only the time interval between brachytherapy and relapse (<1 year) was prognostic for 2-year overall survival (p = .005). CONCLUSION: Salvage surgery is feasible in a very low number of highly selected patients with local relapse following IGABT. Local failure is a major cause of severe local symptoms, confirming that every effort should be done to achieve long-term local control through dose escalation.
引用
- Mignot F, Gouy S, Schernberg A, et al. Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy. Gynecol Oncol. 2020. PMID: 32173045. doi:10.1016/j.ygyno.2020.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。